Questcor Reports Fourth Quarter and Full Year 2011 Financial Results -Q4 2011 Net Sales of $75.5M vs. $29.3M in Q4 2010-

-Q4 2011 Net Income per Diluted Share of $0.48 vs. $0.10 in Q4 2010-

-2011 Net Sales of $218.2 Million vs. $115.1M in 2010-

-2011 Net Income per Diluted Share of $1.21 vs. $0.54 in 2010-

-Conference Call and Webcast to Be Held Today at 4:30 p.m. ET, 1:30 p.m. PT-

ANAHEIM, Calif., Feb. 22, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2011.  

Net sales for the fourth quarter were $75.5 million, reflecting continued physician acceptance of H.P. Acthar® Gel (Acthar) for treating serious, difficult-to-treat medical conditions.  Net sales in the fourth quarter 2010 were $29.3 million.

GAAP net income for the fourth quarter of 2011 was $31.6 million or $0.48 per diluted common share.  GAAP net income for the fourth quarter of 2010 was $6.4 million, or $0.10 per diluted common share.  Non-GAAP net income (which excludes non-cash share-based compensation expense, depreciation and amortization expense, tax adjustments and a goodwill impairment charge) for the quarter ended December 31, 2011 was $31.6 million or $0.47 per diluted common share.  Non-GAAP net income for the year ago quarter was $8.0 million, or $0.12 per diluted common share.

For the year ended December 31, 2011, net sales totaled $218.2 million, compared to $115.1 million in the prior year.  GAAP net income for the year ended December 31, 2011 was $79.6 million or $1.21 per diluted share, compared to GAAP net income of $35.1 million or $0.54 per diluted share for the year ended December 31, 2010.  Non-GAAP net income was $84.0 million or $1.27 per diluted share for the year ended December 31, 2011, compared to non-GAAP net income of $39.0 million or $0.60 per diluted share for the year ended December 31, 2010.

"Net sales growth in the fourth quarter was driven by the increasing numbers of physicians who are recognizing the potential for Acthar to help patients with MS and NS," said Don M. Bailey, President and CEO of Questcor.  "We are particularly encouraged by the growing number of physicians who recognize the therapeutic value of Acthar in their practices, especially for those patients who have not adequately responded to other treatments.  At the same time, we are continuing to build our understanding of the potential immune-modulating properties of Acthar, and are considering how best to study the broader possible therapeutic applications in other inflammatory and autoimmune diseases, many of which are already in the list of approved indications on the Acthar label."  

"The planned expansion of our nephrology sales force from 28 to 58 representatives is underway and should be completed during the second quarter, ahead of our original schedule," noted Steve Cartt, Chief Operating Officer. "We are also planning to increase the number of neurology representatives after the nephrology expansion is complete. Furthermore, a possible pilot commercial effort in rheumatology is being carefully considered for the fourth quarter of this year."

"Paid prescriptions in IS were higher in the fourth quarter, reflecting a growing recognition of the important role of Acthar in treating this devastating condition. As announced yesterday, we were pleased to accept the award from the Child Neurology Foundation (CNF) for outstanding corporate responsibility and leadership, and have further increased our funding to CNF so that they can continue their important research and education efforts related to childhood neurological conditions like IS," added Mr. Cartt.

"Our scientific research and investments continue to expand. In addition to our ongoing studies in NS and MS, we are planning new efforts in Lupus, Diabetic Nephropathy and other auto-immune and inflammatory conditions with unmet medical need," commented Dr. David Young, Chief Scientific Officer. "We have also increased our investigation into better understanding how Acthar works and how its biological activity differs from that of corticosteriods such as methylprednisolone and prednisone."

The Company continues to invest in its management systems and infrastructure, including those related to scientific research, medical affairs, and compliance.  Last week, Questcor announced the appointment of Scott Whitcup, M.D., Chief Scientific Officer of Allergan, Inc., to Questcor's Board of Directors. Also, the Company has recently promoted:

-Steve Cartt to Chief Operating Officer
-Dave Medeiros to Executive Vice President and Chief Technical Officer
-Eldon Mayer to Senior Vice President of Commercial Operations
-Ray Furey to Vice President, Compliance and Chief Compliance Officer
-Gary Hogge, PhD, to Vice President, Medical Affairs.

In addition, Questcor has recently hired Darlene Romine as Vice President, Sales Operations.

"These promotions and additions reflect the expanded needs of Questcor as our sales and headcount have grown and are expected to continue to increase," noted Don Bailey. "I want to congratulate all of these executives on their well-deserved promotions."

Acthar Label Information

The label for Acthar was modernized in October 2010 and has 19 approved indications.  Substantially all of the Company's net sales result from prescriptions written by physicians for the following on-label indications for Acthar:

  • Multiple Sclerosis (MS): "for the treatment of acute exacerbations of multiple sclerosis in adults.  Clinical controlled trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis.  However, there is no evidence that it affects the ultimate outcome or natural history of the disease." Typically Acthar is used as second line treatment for patients with MS exacerbations.
  • Nephrotic Syndrome (NS): "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  NS can result from several underlying conditions, and prescribing physicians indicate that Acthar is most commonly being used in patients who suffer from NS due to idiopathic membranous nephropathy, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, minimal change disease and lupus.
  • Infantile Spasms (IS): "as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age."

The Company is currently planning to explore the potential initiation of a commercial effort in rheumatology in late 2012, as Acthar is approved for the following rheumatology-related conditions:

  • Collagen Diseases: "during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)."
  • Rheumatic Disorders: "as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis."

Shipped Acthar Vial and Prescription Trend Information

During the fourth quarter of 2011, Questcor shipped 3,360 vials of Acthar, compared to 1,680 vials in the year ago quarter.  For the full year of 2011, Questcor shipped 10,710 vials of Acthar compared to 6,696 vials in 2010.  The Company's quarterly vial shipments continue to be subject to significant variation due to the size and timing of individual orders received from Questcor's distributor, and the timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter.  Fourth quarter-ending inventory levels in the channel appear to have remained relatively unchanged compared to the levels at the end of the third quarter of 2011. The Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance.  

Because Acthar prescriptions are filled at specialty pharmacies, the Company does not receive complete information regarding either the number of prescriptions or the number of vials by therapeutic area for all of the patients being treated with Acthar.  However, Questcor is able to monitor trends in payer mix and areas of therapeutic use for new Acthar prescriptions based on data it receives from its reimbursement support center. Questcor estimates that over 90% of new Acthar prescriptions are processed by this support center, but believes that very few refill prescriptions are processed there.

In an effort to help investors better understand historical trends in the prescriptions written for Acthar within each of its current three key therapeutic areas, MS, NS, and IS, Questcor has grouped prescriptions processed by its reimbursement center into two groups -- "Paid" and "Fully Rebated." "Paid" prescriptions include those prescriptions for which Questcor retains its full selling price for Acthar, as well as Tricare prescriptions that subject Questcor to a rebate obligation of up to 24% of its selling price.  "Fully Rebated" prescriptions are those for which Questcor can identify that it has recorded a rebate liability approximately equal to (or for periods prior to January 1, 2010 greater than) Questcor's selling price.  From time to time during the past several years, the rebate liability for some government insurance programs has shifted between these two categories.

Therefore, the prescriptions that fall into the "Paid" and "Fully Rebated" categories have also shifted over time as follows:

"Paid" prescriptions (Rxs) include all prescriptions in the following payer categories:

  • Commercial--For all time periods.
  • Tricare--For 2010 and 2011, but not 2009.
  • Medicaid Managed Care--For all time periods through March 22, 2010 (see Note 1 below the tables).

"Fully Rebated" prescriptions (Rxs) include:

  • Those reimbursed by fee-for-service Medicaid insurance and other state programs eligible for full rebates as Medicaid Waivers Programs for all time periods.
  • Tricare--For 2009.
  • Medicaid Managed Care--For all time periods beginning March 23, 2010 (see Note 1 below the tables).

The following tables show, for each of the three key Acthar therapeutic uses, the number of new prescriptions shipped grouped into "Paid" and "Fully Rebated":

Multiple Sclerosis (and related conditions) New Rxs


Paid

Year-Over-Year

Growth in Paid Rx

Fully Rebated

Total


2009






   Q1-09

78

225%

8

86


   Q2-09

124

254%

17

141


   Q3-09

141

176%

20

161


   Q4-09

213

209%

15

228


   Total 2009

556

211%

60

616


2010






   Q1-10

231

196%

12

243


   Q2-10

304

145%

24

328


   Q3-10

323

129%

19

342


   Q4-10

354

66%

24

378


   Total 2010

1,212

118%

79

1,291


2011






   Q1-11

508

120%

49

557


   Q2-11

751

147%

58

809


   Q3-11

886

174%

46

932


   Q4-11

945

167%

44

989


Total 2011

3,090

155%

197

3,287





Nephrotic Syndrome (and related conditions) New Rxs *



Paid

Fully Rebated

Total


2010





   Q1-10

11

0

11


   Q2-10

4

1

5


   Q3-10

8

0

8


   Q4-10

7

0

7


   Total 2010

30

1

31


2011





   Q1-11

18

1

19


   Q2-11

45

4

49


   Q3-11

60

2

62


   Q4-11

146

19

165


Total 2011

269

26

295




* Questcor commenced commercial efforts in NS in the second quarter of 2011.


Infantile Spasms (and related conditions) New Rxs**



Paid

Fully Rebated

Total


2009





   Q1-09

104

75

179


   Q2-09

91

68

159


   Q3-09

60

58

118


   Q4-09

94

45

139


   Total 2009

349

246

595


2010





   Q1-10

89

48

137


   Q2-10

95

66

161


   Q3-10

92

78

170


   Q4-10

91

68

159


   Total 2010

367

260

627


2011





   Q1-11

89

71

160


   Q2-11

106

79

185


   Q3-11

112

69

181


   Q4-11

120

51

171


Total 2011

427

270

697




** Questcor commenced commercial efforts in IS in the fourth quarter of 2010.

Notes:

(1) Because the March 2010 health care legislation made Medicaid Managed Care Organization (MCO) prescriptions rebate eligible effective March 23, 2010, a rebate liability for the MCO prescriptions estimated to be filled on or after March 23, 2010 has been accrued. The Company does not have the ability to accurately identify every Medicaid Managed Care prescription so it is possible that some prescriptions identified as "Paid" in the tables may subsequently be reclassified as "Fully Rebated."

(2) "Related Conditions" includes diagnoses that are either alternate descriptions of the medical condition or are closely related to the medical condition which is the focus of the table. For example, a prescription for "demyelinating disease of the central nervous system" would be included as an MS-related condition for purpose of this table. About 5% of the prescriptions in the tables are for related conditions.

(3) A prescription may or may not represent a new patient or a new therapy for the patient receiving the prescription.  This can more frequently be the case for NS prescriptions due to the longer treatment regimen for NS.  Questcor uses business rules to determine whether a prescription should be included in this table. From time to time the Company may modify these rules which could cause some changes to the historic numbers in the tables above.

(4) Historical trend information is not necessarily indicative of future results. Additionally, paid prescriptions should not be viewed as predictive of Questcor's net sales due to a variety of factors, including changes in the number of vials used in connection with each prescription.

Cash and Share Repurchase Program

As of February 15, 2012, Questcor's cash, cash equivalents and short-term investments totaled $226 million, and its accounts receivable totaled $44 million.

The Company did not repurchase any shares during the fourth quarter.  As of December 31, 2011, Questcor had 63.6 million shares of common stock outstanding, with 4.3 million shares remaining under its common stock repurchase program.

Sales Reserves

Questcor's sales reserves during the quarter ended December 31, 2011, including the Company's reserves for Medicaid rebates, represented 12% of gross sales of $86.1 million.

As required by federal regulations, Questcor provides rebates to state Medicaid programs for Acthar dispensed to Medicaid patients covered under Medicaid rebate-eligible insurance plans.  Since the Company does not receive rebate claims from the various state Medicaid agencies until well after the close of the quarter in which the underlying sales of vials to its distributor took place, the Company establishes reserves for expected rebate claims on a quarterly basis.  As a result of the adoption of health care reform, for periods after March 23, 2010, the Company has also included in this reserve an estimate for the liability due to states related to prescriptions of Acthar for patients covered under state Medicaid Managed Care Organizations (Medicaid MCO), which prescriptions were not previously rebate eligible.

Questcor experienced a decrease in sales reserves as a percentage of gross sales during each of the four quarters of 2011. The principal reasons for these decreases have been (1) an increase in the percentage of total Acthar prescriptions written to treat adults suffering from MS and NS relative to the percentage used to treat infants suffering from IS, as there is a very high percentage of infants enrolled in Medicaid, and (2) an increase in the number of IS prescriptions being fulfilled through the Acthar free drug program administered by the National Organization for Rare Disorders.  Since September 2007, Questcor has provided $124 million in value through this free drug program.

Conference Call Details

The Company will host a conference call and slide presentation via webcast today, February 22, 2012, at 4:30 p.m. ET/ 1:30 p.m. PT, to discuss fourth quarter and full year 2011 results.  Don Bailey, President and Chief Executive Officer, and other members of the management team will host the call.

To participate in the live call by telephone, please dial (877) 941-0844 for domestic participants and (480) 629-9835 for international participants.  Participants are asked to call the above numbers 5-10 minutes prior to the start time.  A listen-only webcast of the conference call including the presentation slides will be accessible in the "Investor Relations" section under "Events & Presentations" at http://ir.questcor.com/events.cfm.  If listening via telephone, to view the accompanying presentation slides, navigate to the live webcast as noted above and choose the "No Audio — Slides Only" option to view the slides in conjunction with the live conference call.  Listeners should go to the website at least 15 minutes prior to the live conference call to install any necessary software.

An audio replay of the call will be available for 7 days following the call.  This replay can be accessed by dialing (800) 406-7325 for domestic callers and (303) 590-3030 for international callers, both using passcode 4509827#.  An archived webcast will also be available at http://ir.questcor.com/events.cfm.

Use of Non-GAAP Net Income

The Company believes it is important to share non-GAAP financial metrics with shareholders as these metrics may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial metrics. Non-GAAP net income should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP net income.  The reconciliation between GAAP and Non-GAAP net income is provided with the financial tables included with this release.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Questcor currently generates substantially all of its net sales from: the treatment of patients with acute exacerbations of multiple sclerosis in adults, the treatment of patients with nephrotic syndrome, and the treatment of patients with infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, and Dermatomyositis (Polymyositis).  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;
  • Research and development risks, including risks associated with Questcor's work in the area of NS and potential work in the area of Lupus, and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results;
  • Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • Our ability to receive high reimbursement levels from third party payers;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients  and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results;
  • Our ability to effectively manage our growth, including the expansion of our NS selling effort, and our reliance on key personnel;
  • The impact to our business caused by economic conditions;
  • Our ability to protect our proprietary rights;
  • The risk of product liability lawsuits;
  • Unforeseen business interruptions and security breaches;
  • Volatility in Questcor's monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; and
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.

For more information, please visit www.questcor.com or www.acthar.com.

Questcor Pharmaceuticals, Inc.


Consolidated Statements of Income

(In thousands, except per share amounts)


Three Months Ended
December 31,

Twelve Months Ended
December 31,


2011

2010

2011

2010

Revenue





Net sales

$75,535

$  29,296

$  218,169

$115,131

        Cost of sales (exclusive of amortization of purchased technology)

4,013

1,723

12,459

8,013






Gross profit

71,522

27,573

205,710

107,118

Operating expenses:





             Selling and marketing

16,998

11,163

56,728

31,519

             General and administrative

5,766

2,393

17,743

10,279

             Research and development

5,730

3,066

16,778

10,934

             Depreciation and amortization

292

154

1,044

546

             Impairment of goodwill

-

-

299

-

Total operating expenses

28,786

16,776

92,592

53,278

Income from operations

42,736

10,797

113,118

53,840

Interest and other income, net

145

147

627

533

Income before income taxes

42,881

10,944

113,745

54,373

Income tax expense

11,240

4,527

34,154

19,302

Net income

$ 31,641

$  6,417

$79,591

$  35,071






Net income per share:





Basic

$  0.50

$  0.10

$  1.27

$  0.56

Diluted

$  0.48

$  0.10

$  1.21

$  0.54






Shares used in computing net income per share:





Basic

63,236

62,252

62,498

62,112

Diluted

66,565

65,390

66,010

64,741







Reconciliation of Non-GAAP Adjusted Financial Disclosure





Adjusted net income

$31,584

$8,021

$83,956

$38,988

Share-based compensation expense (1)

(1,416)

(598)

(5,128)

(2,649)

Depreciation and amortization expense (2)

(216)

(90)

(731)

(352)

Tax adjustments (3)

1,689

(916)

1,703

(916)

Impairment of goodwill (4)

-

-

(209)

-

Net income – GAAP

$  31,641

$6,417

$79,591

$35,071

Adjusted net income per share – basic

$  0.50

$  0.13

$  1.34

$  0.63

Share-based compensation expense (1)

(0.02)

(0.01)

(0.08)

(0.04)

Depreciation and amortization expense (2)

(0.00)

(0.00)

(0.01)

(0.01)

Tax adjustments (3)

0.03

(0.01)

0.03

(0.01)

Impairment of goodwill (4)

(0.00)

(0.00)

(0.00)

(0.00)

Net income per share – basic

$  0.50

$  0.10

$  1.27

$  0.56






Adjusted net income per share – diluted

$  0.47

$  0.12

$  1.27

$  0.60

Share-based compensation expense (1)

(0.02)

(0.01)

(0.08)

(0.04)

Depreciation and amortization expense (2)

(0.00)

(0.00)

(0.01)

(0.01)

Tax adjustments (3)

0.03

(0.01)

0.03

(0.01)

Impairment of goodwill (4)

(0.00)

(0.00)

(0.00)

(0.00)

Net income per share – diluted

$  0.48

$  0.10

$  1.21

$  0.54




Net income per share – basic and diluted may not foot due to rounding.

Use of Non-GAAP Financial Measures

Our "non-GAAP adjusted net income" excludes the following items from GAAP net income:

(1)

Share-based compensation expense.

(2)

Depreciation and amortization expense

(3)

Tax adjustments include: (1) the valuation allowance we established in the fourth quarter of 2010 relating to our single sales factor apportionment election which was made in 2011 for California; (2) the recording of a one-time tax credit in 2011 for the orphan drug designation; and (3) the reserve for the liability associated with the Ohio Commercial Activity Tax for the period 2007 – 2010 (the expense associated with this reserve is included in operating expenses).

(4)

Impairment of goodwill related to the write-off of goodwill associated with an acquisition transaction completed in 1999.



Questcor Pharmaceuticals, Inc.


Consolidated Balance Sheets

(In thousands, except share amounts)


December 31,

2011

December 31,

2010  

ASSETS



Current assets:



Cash and cash equivalents

$           88,469

$  41,508

Short-term investments

121,680

73,324

Total cash, cash equivalents and short-term investments

210,149

114,832

Accounts receivable, net of allowances of $0 and $25 at December 31, 2011 and 2010, respectively

27,801

11,128

Inventories, net of allowances of $0 and $158 at December 31, 2011 and 2010, respectively

5,226

3,726

Prepaid income taxes

6,940

3,532

Prepaid expenses and other current assets

3,391

1,864

Deferred tax assets

12,093

8,417

Total current assets

265,600

143,499

Property and equipment, net

1,970

872

Purchased technology, net

2,778

3,074

Goodwill

-

299

Deposits and other assets

56

65

Deferred tax assets

5,404

4,184

Total assets

$  275,808

$  151,993




LIABILITIES AND SHAREHOLDERS' EQUITY



Current liabilities:



Accounts payable

$  5,503

$  3,869

Accrued compensation

11,590

4,158

Sales-related reserves

34,119

21,511

Other accrued liabilities

4,509

1,973

Total current liabilities

55,721

31,511

Lease termination, deferred rent and other non-current liabilities

261

355

Total liabilities

55,982

31,866







Shareholders' equity:



Preferred stock, no par value, 7,500,000 shares authorized; none outstanding

-

-

Common stock, no par value, 105,000,000 shares authorized, 63,645,781 and 62,418,464 shares issued and outstanding at December 31, 2011 and 2010, respectively

94,976

74,809

Retained earnings

124,886

45,295

Accumulated other comprehensive income

(36)

23

Total shareholders' equity

219,826

120,127

Total liabilities and shareholders' equity

$  275,808

$  151,993







Questcor Pharmaceuticals, Inc.


Consolidated Statements of Cash Flows

(In thousands)


Year Ended

December 31,


2011

2010

OPERATING ACTIVITIES



Net income

$  79,591

$  35,071

Adjustments to reconcile net income to net cash provided by operating activities:



Share-based compensation expense

7,326

3,739

Deferred income taxes

(4,896)

(1,029)

Amortization of investments

1,250

678

Depreciation and amortization

1,044

546

Impairment of goodwill

299

-

Loss on disposal of property and equipment

11

-

Changes in operating assets and liabilities:



Accounts receivable

(16,673)

3,705

Inventories

(1,500)

(348)

Prepaid income taxes

(3,408)

(3,532)

Prepaid expenses and other current assets

(1,527)

(702)

Accounts payable

1,634

(9,052)

Accrued compensation

7,432

2,018

Sales-related reserves

12,608

6,589

Other accrued liabilities

2,526

(255)

Other non-current liabilities

(118)

(871)

Net cash flows provided by operating activities

85,599

36,557




INVESTING ACTIVITIES



Purchase of property and equipment

(1,823)

(713  )

Purchase of short-term investments

(162,301)

(106,647)

Proceeds from maturities of short-term investments

112,636

62,560

Deposits and other assets

9

645

Net cash flows used in investing activities

(51,479)

(44,155)




FINANCING ACTIVITIES



Income tax benefit realized from share-based compensation plans

17,712

1,335

Issuance of common stock, net

6,582

1,942

Repurchase of common stock

(11,453)

-

Net cash flows provided by financing activities

12,841

3,277




Increase (decrease) in cash and cash equivalents

46,961

(4,321)

Cash and cash equivalents at beginning of period

41,508

45,829

Cash and cash equivalents at end of period

$  88,469

$  41,508




Supplemental Disclosures of Cash Flow Information:



Cash paid for interest

$          16

$           7

Cash paid for income taxes

$   25,278

$  23,185




Supplemental Disclosures of Non-Cash Investing and Financing Activities:



Capital lease obligation

$          34

$           -







SOURCE Questcor Pharmaceuticals, Inc.



RELATED LINKS
http://www.questcor.com
http://www.acthar.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.